Analysis of claims data finds patients often receive starting doses of Butrans (buprenorphine) that do not follow published recommendations, with more than one-third of patients receiving initial doses that are too low.

A report from IMS Institute for Healthcare Informatics finds that per capita medication spending dropped 3.5% in 2012—the first decline since the organization began tracking drug spending in 1957.

A diabetes care team that included a clinical pharmacist led to major improvements in glycemic control, LDL cholesterol levels, blood pressure, and long-term cardiovascular risk.